SCHEMBL1115898

SCHEMBL1115898

COC(=O)c1cc(OC)cc2nc(Nc3cccc(Cl)c3Cl)[nH]c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
CSF1R P07333 4/20 0.42
MAPK14 Q16539 2/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
HDAC11 Q96DB2 1/20 0.39
FABP3 P05413 1/20 0.39
FABP4 P15090 1/20 0.39
CDK9 P50750 3/20 0.38
DYRK1A Q13627 2/20 0.38
DYRK2 Q92630 1/20 0.38
DYRK1B Q9Y463 1/20 0.38
MAPK1 P28482 1/20 0.38
NR4A2 P43354 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
MET P08581 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1115902 0.92 FABP3 (0.45) MAPTCSF1RKMT2AMEN1HDAC11
SCHEMBL1116014 0.89 MAPT (0.46) MAPTCSF1RMAPK14KMT2AMEN1
SCHEMBL2932084 0.88 MAPT (0.44) MAPTCSF1RMAPK14KMT2AMEN1
SCHEMBL1115894 0.88 MAPT (0.44) MAPTCSF1RMAPK14KMT2AMEN1
SCHEMBL1115897 0.85 MAPT (0.42) MAPTCSF1RMAPK14KMT2AMEN1
SCHEMBL1115889 0.83 MAPT (0.43) MAPTCSF1RMAPK14KMT2AMEN1
SCHEMBL1116255 0.77 MAPT (0.46) MAPTKMT2AMEN1FABP3FABP4
SCHEMBL12856603 0.75 MAPT (0.46) MAPTKMT2AMEN1FABP3FABP4
SCHEMBL1116024 0.75 MAPT (0.44) MAPTCSF1RKMT2AMEN1FABP3
SCHEMBL12856631 0.75 MAPT (0.44) MAPTCSF1RKMT2AMEN1FABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2281819-A1 Benzimidazolyl or benzoxazolyl derivatives Novartis AG (CH) 2011-02-09 EP disclosed
US-20090298824-A1 Organic compounds PRESS NEIL J 2009-12-03 US disclosed
EP-1709015-A1 ORGANIC COMPOUNDS Novartis AG (CH) 2006-10-11 EP disclosed
WO-2005070906-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298824-A1 Organic compounds CXCR2, CXCR3, CXCR1 MAPT 4012/4885CSF1R 340/4885MAPK14 3145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.